



Triterpenoids From *Alisma* **Species: Phytochemistry, Structure Modification, and Bioactivities**

Pengli Wang^{\dagger}, Tongxin Song^{\dagger}, Rui Shi, Mingshuai He, Rongrong Wang, Jialin Lv and Miaomiao Jiang^{*}

Tianjin Key Laboratory of TCM Chemistry and Analysis, Institute of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China

Plants from *Alisma* species belong to the genus of *Alisma* Linn. in *Alismataceae* family. The tubers of *A. orientale* (Sam.) Juzep, also known as *Ze Xie* in Chinese and *Takusha* in Japanese, have been used in traditional medicine for a long history. Triterpenoids are the main secondary metabolites isolated from *Alisma* species, and reported with various bioactive properties, including anticancer, lipid-regulating, anti-inflammatory, antibacterial, antiviral and diuretic activities. In this brief review, we aimed to summarize the phytochemical and pharmacological characteristics of triterpenoids found in *Alisma*, and discuss their structure modification to enhance cytotoxicity as well.

OPEN ACCESS

Edited by:

Toshio Morikawa, Kindai University, Japan

Reviewed by:

Michele Mari, University of Urbino Carlo Bo, Italy Yuanqiang Guo, Nankai University, China

*Correspondence:

Miaomiao Jiang miaomiaojiang@tjutcm.edu.cn

[†]These authors have contributed equally to this work

Specialty section:

This article was submitted to Organic Chemistry, a section of the journal Frontiers in Chemistry

Received: 22 December 2019 Accepted: 08 April 2020 Published: 30 April 2020

Citation:

Wang P, Song T, Shi R, He M, Wang R, Lv J and Jiang M (2020) Triterpenoids From Alisma Species: Phytochemistry, Structure Modification, and Bioactivities. Front. Chem. 8:363. doi: 10.3389/fchem.2020.00363 Keywords: triterpenoids, Alisma, structure, anticancer, lipid-regulation

INTRODUCTION

Plants from the genus of *Alisma* Linn. (*Alismataceae*) are widely distributed in temperate regions and subtropics of the northern hemisphere, belonging to 11 species. Six species were found in China and Asia, including *A. canaliculatum*, *A. gramineum*, *A. nanum*, *A. orientale*, *A. plantago-aquatica* and *A. lanceolatum* (Flora of China Committee, 1992). The tubers of *A. orientale*, known as *Ze Xie* in Chinese or *Takusha* in Japanese, have been used as diuretic and detumescent medications for a long history (Chinese Pharmacopoeia Commission, 2015). It is also used to treat obesity, diabetes and hyperlipidemia nowadays.

Phytochemical studies have revealed that triterpenoids are dominant components in tubers of *Alisma* plants. A total of 118 triterpenoids have been isolated and identified from *Alisma* species so far. Most of them contain protostane tetracyclic aglycones, whereas glycosides are rarely found in other plants. These triterpenoids have been considered as chemotaxonomic markers of the genus (Zhao et al., 2007). A small amount of other kinds of compounds have also been isolated from A. orientale, including diterpenoids, sesquiterpenoids, polysaccharides, phytosterols, amino acids, flavonoids and fatty acids (Zhang et al., 2017). The presence of triterpenoids attributes to the bioactivities of A. orientales (Tian et al., 2014; Shu et al., 2016), such as alisol A 24-acatate (2), and alisol B 23-acetate (47) (Choi et al., 2019).

Alisols have shown a series of biological activities, such as anticancer (Law et al., 2010), lipid-regulating (Cang et al., 2017), anti-inflammatory (Kim et al., 2016), antibacterial (Jin et al., 2012), antiviral (Jiang et al., 2006), and diuretic activities (Zhang et al., 2017). Since alisol B 23-acetate (47) exhibits a significant anti-tumor activity, structure-based modification on alisol B 23-acetate (47) gives a profound change of activity.

This paper aims to systematically review triterpenoids from *Alisma* species, involving their phytochemical characteristics, biosynthesis, bioactivities and structure modification.

TRITERPENOIDS

Starting from 1968, triterpenoids have been isolated from *Alisma* genus successively (Murata et al., 1968). All these compounds contain protostane tetracyclic skeleton with the structural characteristics of *trans*-fusions for A/B, B/C and C/D rings, α -methyl submitted at C-8, β -methyl at C-10, β -methyl at C-14 and side chain at C-17. At present there are 101 protostane triterpenoids, 12 nor-protostanes, and 5 seco-protostanes reported from *Alisma*. According to the changes of side chains submitted at C-17, protostane triterpenoids from *Alisma* are divided into four classes, including open aliphatic chains, epoxy aliphatic chains, spiro hydrocarbon at C-17, and epoxy at C-16, C-23 or C-16, C-24. The individual triterpenoids were detailed in **Table 1**.

Protostanes With Open Aliphatic Chains at C-17

Forty-five protostanes with open aliphatic chains at C-17 (1– 45) have been identified as shown in **Figure 1**. Alisol A (1) is a representative compound of this type. Hydroxyl groups may substitute at C-29 (11) (Wang et al., 2017b), disubstitute at C-23/C-24 (19) and C-23/C-25 (43-45) (Nakajma et al., 1994; Peng et al., 2002b), or trisubstitute at C-23, C-24, and C-25 (41, 42). The hydroxyl group at C-23 or C-24 is easily acetylated. Moreover, double bond may form at C-25 and C-26 (38, 39) (Han et al., 2013), or C-25 may be substituted by carboxyl group (31) (Zhao et al., 2013).

Carbonyl groups substitute at C-16 (8, 9) (Zhao et al., 2015), disubstitute at C-7/C-16 (41) (Mai et al., 2015) or C-16/C-23 (21) (Yoshikawa et al., 1999), or substitute at C-24 (37) (Xu et al., 2012) or C-23 (23) (Yi et al., 2019). Hydroxymethyl groups substitute at C-16 (18) (Li et al., 2017) or disubstitute at C-16/C-25 (19).

Protostanes With Epoxy Aliphatic Chains at C-17

Thirty-six protostanes with epoxy aliphatic chains at C-17 (**46**-**81**) have been found in the genus of *Alisma* and their structures are listed in **Figure 2**. Alisol B 23-acetate (**47**) is a representative compound of this type. Epoxy group usually forms at C-24 and C-25 (**46**-**73**, **77**-**79**, **81**) (Fukuyama et al., 1988), and C-23 may be substituted by hydroxyl (**66**) or acetoxyl group (**67**-**71**).

Except for epoxy ring, tetrahydrofuran ring from C-20 to C-24 (74, 75) and seven-membered peroxic ring from C-20 to C-25 (76) are also existed in the side chains at C-17.

Protostanes With Spiro Hydrocarbon at C-17

Eight protostanes with spiro hydrocarbon at C-17 (82–89) have been isolated from the genus of *Alisma* as shown in **Figure 3**. Oxaspiro-nonane moiety is generated between D ring and its side chain with C-17 as spiro hydrocarbon. Methyl group substituted at C-20 with α - (82) (Xin et al., 2016) or β - (85) (Jin et al., 2019) conformation. Alisol U (83) differs from alisol V (84) by forming an epoxy at C-24 and C-25.

Protostanes With Fused Ring at C-16 and C-17

Twelve protostanes with fused-ring at C-16 and C-17 (90– 101) have been isolated from *Alisma* as shown in Figure 4. Tetrahydropyrane ring is fused at C-16 and C-17 (90–98) (Yoshikawa et al., 1993; Peng and Lou, 2001; Hu et al., 2008a,b; Chen et al., 2018). Oxacycloheptane ring is fused at C-16 and C-17 (99–101). Alismanol J (101) differs from alismaketone B-23-acetate (99) by forming an oxygen bridge between C-16 and C-23.

Nor- and seco-protostanes

Twelve nor-protostanes (102–113) have been found in *Alisma*, including two demethyl-protostanes (102, 103) and ten tetranorprotostanes (104–113). Among C-2 may be submitted by carbanyl group (109) (Mai et al., 2015). The configuration of C-17 is determined (107, 108) (Xin et al., 2018).

Only five seco-protostanes (114–118) have been known in *Alisma*, including two 13, 17-seco-protostanes (114, 115) (Matsuda et al., 1999; Wang et al., 2017a) and three 2, 3-secoprotostanes (116–118) (Yoshikawa et al., 1997). Their structures were detailed in Figure 5.

BIOSYNTHESIS

Alisma triterpenoids is commonly biosynthesized through mevalonic aid (MVA) pathway (Zhang et al., 2018) as shown in **Figure 6**. Three molecules of acetyl-CoA are catalyzed by enzymes to form mevalonate acid (MVA) (Vinokur et al., 2014). It is catalyzed by mevalonate pyrophosphate decarboxylase to produce isopentyl pyrophosphate (IPP), which reacts with dimethylallyl pyrophosphate (DMAPP) to generate geranyl pyrophosphate (GPP) by farnesyl pyrophosphate synthase of *A.* orientale (AOFPPS) (Peng et al., 2018). Squalene is synthesized by squalene synyase of *A. orientale* (AOSS) (Shen et al., 2013), which is then catalyzed by squalene epoxidase of *A. orientale* (AOSE) to produce 2,3-oxidosqualeneand further to form protostane tetracyclic skeleton (Zhang et al., 2018). AOFPPS and AOSS are rate-limiting enzymes in *Alism*a triterpenoids biosynthesis pathway (Zhou et al., 2018).

Fresh materials of *A. orientalis* are naturally rich in alisol B 23acetate (47) (Zhu and Peng, 2006), which can convert into alisol A 24-acetate (2), alisol A (1), and alisol B (46) after processing at high temperature (Zheng et al., 2006). Other triterpenoids, such as alisol A (1) (Peng et al., 2002a) and their derivatives, were formed during the drying process (Yoshikawa et al., 1994).

BIOACTIVITIES

Alisma orientale is traditionally used to treat oliguria, edema, gonorrhea with turbid urine, leukorrhea, diarrhea, dizziness and hyperlipidemia (Chinese Pharmacopoeia Commission, 2015). Modern pharmacological studies have demonstrated its diuretic and lipid-lowering efficiency, together with anticancer, lipid-regulating, anti-inflammatory, antibacterial, antiviral activities.

TABLE 1 | A total of 118 triterpenoids isolated and identified from Alisma genus.

No.	Name	Skeleton structure	R ₁	R ₂	R ₃	R4	R ₅	R ₆	Double bond position	Source	References
PROT	OSTANES WITH OPEN ALIPHATIC C	HAINS AT C	-17								
1	alisol A	А	βΟΗ	Н	βΟΗ	βΟΗ	OH	Н	$\Delta^{13(17)}$	A. orientalis	Peng et al., 2002a
2	alisol A 24-acetate	A	βΟΗ	Н	βΟΗ	βOAc	OH	Н	$\Delta^{13(17)}$	A. orientalis	Peng et al., 2002a
3	alisol A 23-acetate	А	βΟΗ	Н	βOAc	βΟΗ	OH	Н	$\Delta^{13(17)}$	A. orientalis	Peng et al., 2002a
4	11-deoxyalisol A	A	Н	Н	βΟΗ	βΟΗ	OH	Н	$\Delta^{13(17)}$	A. orientalis	Peng et al., 2002b
5	23-o-methyl alisol A	А	βΟΗ	Н	βOMe	βΟΗ	OH	Н	$\Delta^{13(17)}$	A. orientale	Nakajma et al., 1994
6	25-o-methoxy-alisol A	А	βΟΗ	Н	βΟΗ	βΟΗ	OMe	Н	$\Delta^{13(17)}$	A. orientale	Nakajma et al., 1994
7	16-oxo-alisol A	А	βΟΗ	0	βΟΗ	βΟΗ	OH	Н	$\Delta^{13(17)}$	A. orientale	Mai et al., 2015
8	16-oxo-alisol A-23-acetate	А	βΟΗ	0	βOAc	βΟΗ	OH	Н	$\Delta^{13(17)}$	A. orientale	Zhao et al., 2015
9	16-oxo-alisol A-24-acetate	А	βΟΗ	0	βΟΗ	βOAc	OH	Н	$\Delta^{13(17)}$	A. orientale	Zhao et al., 2015
10	16-oxo-11-deoxy- alisol A	А	Н	0	βΟΗ	βΟΗ	OH	Н	$\Delta^{13(17)}$	A. orientale	Mai et al., 2015
11	5 β ,29-dihydroxy alisol A	Α (5βΟΗ)	βΟΗ	Н	βΟΗ	βΟΗ	ОН	ОН	$\Delta^{13(17)}$	A. plantago- aquatica	Wang et al., 2017b
12	25-o-butyl alisol A	А	βΟΗ	Н	βΟΗ	βΟΗ	OBu	Н	$\Delta^{13(17)}$	A. orientalis	Zhang et al., 2017
13	alisol E	А	βΟΗ	Н	βΟΗ	αΟΗ	OH	Н	$\Delta^{13(17)}$	A. orientale	Yoshikawa et al., 1993
14	alisol E-23-acetate	А	βΟΗ	Н	βOAc	αΟΗ	OH	Н	$\Delta^{13(17)}$	A. orientale	Yoshikawa et al., 1993
15	alisol E-24-acetate	А	βΟΗ	Н	βΟΗ	αOAc	OH	Н	$\Delta^{13(17)}$	A. orientale	Yoshikawa et al., 1993
16	25-o-ethylalisol A	А	βΟΗ	Н	βΟΗ	βΟΗ	OEt	Н	$\Delta^{13(17)}$	A. orientale	Mai et al., 2015
17	alisol H	А	Н	0	0	Н	OH	Н	$\Delta^{13(17)}$	A. orientale	Yoshikawa et al., 1999
18	16β-methoxyalisol E	А	βΟΗ	βOMe	βΟΗ	αΟΗ	OH	Н	$\Delta^{13(17)}$	A. orientale	Li et al., 2017
19	16β,25-dimethoxyalisol E	A	βOH	βOMe	βΟΗ	αΟΗ	OMe	Н	$\Delta^{13(17)}$	A. orientale	Li et al., 2017
20	16β-hydroperoxyalisol E	А	βOH	βΟΟΗ	βΟΗ	αΟΗ	OH	Н	$\Delta^{13(17)}$	A. orientale	Li et al., 2017
21	11,24-dihydroxy-alisol H	A	βOH	0	0	βΟΗ	OH	Н	$\Delta^{13(17)}$	A. orientale	Yoshikawa et al., 1999
22	alisol T	A	βOH	βOMe	OH	Н	OH	Н	$\Delta^{13(17)}$	A. orientale	Li et al., 2017
23	alismanin I	A	βOH	Н	0	OH	Н	Н	$\Delta^{13(17)}$	A. orientale	Yi et al., 2019
24	15,16-dihydroalisol A.	A	βOH	Н	βΟΗ	βΟΗ	OH	Н	$\Delta^{13(17),15(16)}$	A. orientale	Mai et al., 2015
25	alismanol D	A	Н	Н	Н	αOH	OH	Н	$\Delta^{9(11),12(13)}$	A. orientale	Mai et al., 2015
26	24-epi-alismanol D	A	Н	Н	Н	βΟΗ	OH	Н	$\Delta^{9(11),12(13)}$	A. orientalis	Xin et al., 2018
27	alismanol A	A	Н	0	0	αOH	OH	Н	$\Delta^{11(12),13(17)}$	A. orientale	Mai et al., 2015
28	alismanol C	A	Н	0	βOAc	αOH	OH	Н	$\Delta^{11(12),13(17)}$	A. orientale	Mai et al., 2015
29	16-oxo-11-anhydro alisol A	A	Н	0	βОН	βОН	OH	Н	$\Delta^{11(12),13(17)}$	A. orientale	Mai et al., 2015
30	16-oxo-11-anhydroalisol A 24-acetate	A	Н	0	βОН	βOAc	OH	Н	$\Delta^{++(12),+3(17)}$	A. orientale	Ma et al., 2016
31	3-oxo-11β,23-dihydroxy-24,24- dimethyl—26,27-dinorprotost- 13(17)-en-25-oic-acid	A	βОН	0	Н	βОН	СООН	Н	$\Delta^{13(17)}$	A. orientale	Zhao et al., 2013
32	alismanin B	A	βOH	0	Н	βΟΗ	Н	Н	$\Delta^{13(17)}$	A. orientale	Wang et al., 2017a
33	25-anhydroalisol A	В	βOH	Н	βΟΗ	βΟΗ			$\Delta^{13(17)}$	A. orientalis	Peng et al., 2002a
34	11-acetate-25-anhydroalisol A	В	βOAc	Н	βΟΗ	βΟΗ			$\Delta^{13(17)}$	A. orientalis	Peng et al., 2002a
35	24-acetate-25-anhydroalisol A	В	βOH	Н	βΟΗ	βOAc			$\Delta^{13(17)}$	A. orientalis	Peng et al., 2002a
36	11-deoxy-25-anhydro-alisol E.	В	Н	Н	βΟΗ	αOH			$\Delta^{13(17)}$	A. orientale	Mai et al., 2015
37	alisol X	В	βOH	Н	Н	0			$\Delta^{13(17)}$	A. orientale	Xu et al., 2012
38	23-acetate-25-anhydroalisol E	В	Н	Н	βOAc	αOH			$\Delta^{13(17)}$	A. orientalis	Han et al., 2013
39	24-acetate-25-anhydroalisol E	В	Н	Н	βОН	αΟΑς			$\Delta^{13(17)}$	A. orientalis	Han et al., 2013
40	alismanol B	В	Н	0	βΟΗ	αOH			$\Delta^{11(12),13(17)}$	A. orientale	Mai et al., 2015
41	7-oxo-16-oxo-11-anhydro alisol A	С								A. orientale	Mai et al., 2015
42	alismanol M	D								A. orientale	Xin et al., 2016
43	13,17-epo-alisol A	E -	βOH	αOH						A. orientalis	Peng et al., 2002b
44	13,17-epoalísol A 24-acetate	E	βOH	αOAc						A. orientalis	Peng et al., 2002b
45	11-deoxy-13,17-epoxy-alisol A	F	Н	βΟΗ						A. orientale	Nakajma et al., 1994

(Continued)

TABLE 1 | Continued

No.	Name	Skeleton structure	R ₁	R ₂	R ₃	R ₄	R ₅	R ₆	Double bond position	Source	References
PROT	OSTANES WITH EPOXY ALIPHATIC	CHAINS AT (C-17								
46	alisol B	F	βΟΗ	Н	Н	Н	αMe	βΟΗ	$\Delta^{13(17)}$	A. orientale	Nakajma et al., 1994
47	alisol B 23-acetate	F	βΟΗ	Н	Н	Н	αMe	βOAc	$\Delta^{13(17)}$	A. orientale	Nakajma et al., 1994
48	11-deoxy-alisol B-23-acetate	F	Н	Н	Н	Н	βMe	βOAc	$\Delta^{13(17)}$	A. orientale	Nakajma et al., 1994
49	11-deoxy-alisol B	F	Н	Н	Н	Н	βMe	βΟΗ	$\Delta^{13(17)}$	A. orientale	Nakajma et al., 1994
50	16β-acetoxy alisol B	F	βΟΗ	Н	βOAc	Н	αMe	βΟΗ	$\Delta^{13(17)}$	A. orientalis	Cang et al., 2017
51	16α-acetoxy alisol B	F	βΟΗ	Н	αOAc	Н	αMe	βΟΗ	$\Delta^{13(17)}$	A. orientalis	Cang et al., 2017
52	16β-hydroxyalisol B-23-acetate	F	βΟΗ	Н	βΟΗ	Н	αMe	βOAc	$\Delta^{13(17)}$	A. orientalis	Peng and Lou, 2001
53	16β-methoxyalisol B-23- acetate	F	βΟΗ	Н	βOMe	Н	αMe	βOAc	$\Delta^{13(17)}$	A. orientale	Jin et al., 2012
54	16β-ethoxy alisol B 23-acetate	F	βΟΗ	Н	βOEt	Н	αMe	βOAc	$\Delta^{13(17)}$	A. orientalis	Zhang et al., 2017
55	alisol C	F	βΟΗ	Н	0	Н	αMe	βΟΗ	$\Delta^{13(17)}$	A. orientale	Nakajma et al., 1994
56	11-deoxy-alisol C-23-acetate	F	Н	Н	0	Н	αMe	βOAc	$\Delta^{13(17)}$	A. orientale	Nakajma et al., 1994
57	11-deoxy-alisol C	F	Н	Н	0	Н	αMe	βΟΗ	$\Delta^{13(17)}$	A. plantago- aquatica	Fukuyama et al., 1988
58	20-hydroxyalisol C	F	βΟΗ	Н	0	OH	αMe	βΟΗ	$\Delta^{13(17)}$	A. orientale	Mai et al., 2015
59	alisol C 23-acetate	F	βΟΗ	Н	0	Н	αMe	βOAc	$\Delta^{13(17)}$	A. plantago- aquatica	Fukuyama et al., 1988
60	alisol M-23-acetate	F	βΟΗ	βΟΗ	0	Н	αMe	βOAc	$\Delta^{13(17)}$	A. orientale	Li et al., 2017
61	alisol N-23-acetate	F	βΟΗ	βΟΗ	Н	Н	αMe	βOAc	$\Delta^{13(17)}$	A. orientale	Li et al., 2017
62	16β-hydroperoxyalisol B	F	βΟΗ	Н	βΟΟΗ	Н	αMe	βΟΗ	$\Delta^{13(17)}$	A. orientale	Li et al., 2017
63	16β-hydroperoxyalisol B 23-acetate	F	βΟΗ	Н	βΟΟΗ	Н	αMe	βOAc	$\Delta^{13(17)}$	A. orientale	Li et al., 2017
64	alisol L	F	Н	Н	0	Н	αMe	βΟΗ	$\Delta^{11(12),13(17)}$	A. orientale	Zhao et al., 2015
65	alisol L-23-acetate	F	Н	Н	0	Н	αMe	βOAc	$\Delta^{11(12),13(17)}$	A. orientale	Yoshikawa et al., 1999
66	13β,17β-epoxy-alisol B	G	βΟΗ	βΟΗ						A. orientale	Nakajma et al., 1994
67	13β,17β-epoxy-23- acetate-alisol B	G	βΟΗ	βOAc						A. orientale	Jin et al., 2012
68	11-deoxy-13β,17β-epoxy-alisol B 23-acetate	G	Н	βOAc						A. orientale	Nakajma et al., 1994
69	alisol D	G	βΟΗ	αΟΑς						A. plantago- aquatica	Fukuyama et al., 1988
70	alisol D 11-acetate	G	βOAc	αΟΑς						A. plantago- aquatica	Fukuyama et al., 1988
71	11-deoxyalisol D	G	Н	αΟΑς						A. orientale	Yoshikawa et al., 1999
72	alisol J–23 acetate	Н								A. orientale	Yoshikawa et al., 1999
73	alisol K-23-acetate	I								A. orientale	Yoshikawa et al., 1999
74	alismanol O	J	Н							A. orientale	Xin et al., 2016
75	alismanol P	J	αΟΗ							A. orientale	Xin et al., 2016
76	alisolide H	К								A. plantago- aquatica	Jin et al., 2019
77	alisolide G	L	0	αΟΑς						A. plantago- aquatica	Jin et al., 2019
78	alisol Q 23-acetate	L	0	βOAc						A. orientale	Jin et al., 2012
79	alisol S 23-acetate	L	βΟΗ	βOAc						A. orientale	Li et al., 2017
80	alisolide I	Μ								A. plantago- aquatica	Jin et al., 2019
81	alismaketone A-23-acetate	Ν								A. orientale	Yoshikawa et al., 1997
PROT	OSTANES WITH SPIRO HYDROCAR	BON AT C-17	7								
82	alismanol Q	0								A. orientale	Xin et al., 2016
83	alisol U	Ρ								A. orientale	Li et al., 2017
84	alisol V	Q								A. orientale	Li et al., 2017
85	alisolide D	R								A. plantago- aquatica	Jin et al., 2019

(Continued)

TABLE 1 | Continued

No.	Name	Skeleton structure	R ₁	R ₂	R ₃	R ₄	R ₅	R ₆	Double bond position	Source	References
86	alisolide E	S	βOH						$\Delta^{12(13)}$	A. plantago- aquatica	Jin et al., 2019
87	alisolide F	S	Н						$\Delta^{9(11), 12(13)}$	A. plantago- aquatica	Jin et al., 2019
88	neoalisol	Т	βΟΗ	βΟΗ						A. orientalis	Peng et al., 2002a
89	neoalisol 11.24-diacetate	Т	βOAc	βOAc						A. orientalis	Peng et al., 2002a
PROT	OSTANES WITH FUSED RING AT C-	16 AND C-17	'								
90	16,23-oxidoalisol B	U	βΟΗ						$\Delta^{13(17)}$	A. orientale	Nakajma et al., 1994
91	alisol I	U	βΗ						$\Delta^{13(17)}$	A. orientale	Yoshikawa et al., 1999
92	alisol F	V	βΟΗ	βΟΗ	OH				$\Delta^{13(17)}$	A. orientale	Yoshikawa et al., 1993
93	alisol F-24-acetate	V	βΟΗ	βOAc	OH				$\Delta^{13(17)}$	A. orientalis	Peng and Lou, 2001
94	25-o-methylalisol F	V	βΟΗ	βΟΗ	OMe				$\Delta^{13(17)}$	A. orientalis	Chen et al., 2018
95	11-anhydroalisol F	V	Н	βΟΗ	OH				$\Delta^{11(12),13(17)}$	A. orientalis	Hu et al., 2008a
96	alisol O	V	Н	βOAc	ОН				$\Delta^{11(12),13(17)}$	A. plantago- aquatica	Jiang et al., 2006
97	25-anhydroalisol F	W	βΟΗ						$\Delta^{13(17)}$	A. orientalis	Hu et al., 2008a
98	11,25-anhydro-alisol F	W	Н						$\Delta^{11(12),13(17)}$	A. orientalis	Hu et al., 2008b
99	alismaketone B-23-acetate	Х	βΟΗ	αOAc					$\Delta^{13(17)}$	A. orientale	Matsuda et al., 1999
100	alismanol E	Х	Н	0					$\Delta^{11(12),13(17)}$	A. orientale	Mai et al., 2015
101	alismanol J	Y								A. orientalis	Zhang et al., 2017
NOR-	PROTOSTANES										-
102	alismanol H	Z	н	Me						A. orientalis	Zhang et al., 2017
103	alismanin A	Z	C_6H_5	Н						A. orientale	Wang et al., 2017a
104	alisolide A	а	0	βΟΗ					C-17R	A. plantago- aquatica	Jin et al., 2019
105	alisolide B	а	0	βΟΟΗ					C-17S	A. plantago- aquatica	Jin et al., 2019
106	alisolide C	а	βOH	βΟΗ					C-17S	A. plantago- aquatica	Jin et al., 2019
107	alisolide	b								A. orientalis	Xin et al., 2018
108	17-epi-alisolide	С								A. orientalis	Xin et al., 2018
109	alismanol F	d								A. orientale	Mai et al., 2015
110	alismanol G	е	Н	0	Ac				$\Delta^{11(12),13(17)}$	A. orientale	Mai et al., 2015
111	alismanol I	е	βΟΗ	0	ОН				$\Delta^{13(17)}$	A. orientalis	Zhang et al., 2017
112	alisol R	е	βΟΗ	Н	0				$\Delta^{12(13)}$	A. orientale	Li et al., 2017
113	13β,17β-epoxy-24,25,26,27 -tetranor-alisol A 23-oic acid	f								A. orientale	Zhao et al., 2007
SECO	-PROTOSTANES										
114	alismanin C	g								A. orientale	Wang et al., 2017a
115	alismaketone C-23-acetate	h								A. orientale	Matsuda et al., 1999
116	alismalactone-23-acetate	i	Н							A. orientale	Yoshikawa et al., 1997
117	3-methyl-alismalactone 23-acetate	i	Me							A. orientale	Yoshikawa et al., 1997
118	alisol P	j								A. orientale	Zhao et al., 2007

Anticancer Activities

Recently, the experiments *in vitro* highlight that alisols induce apoptosis and autophagy in human tumor cells, such as lung cancer (Wang et al., 2018), ovarian cancer (Zhang et al., 2016), and prostate cancer (Huang et al., 2006) cell lines. The cytotoxicities of alisol B 23-acetate (47), cancer cell lines, including L1210 and K562 leukemia alisol C 23-acetate (59), alisol B (46) and alisol A 24-acetate (2) are examined on several cells, B16-F10 melnoma cells, A549 lung adenocarcinoma cells, SK-OV3 ovarian cells, HT 1080 fibrosarcoma cells. The results show that alisol B 23-acetate (47), alisol C 23-acetate (59) and alisol A 24-acetate (2) have weaker inhibitory activities against all the tested cancer cells with ED₅₀ values in the range of 10~20 μ g/ml, while alisol B (46) exhibits significant effect on SK-OV3, B16-F10, and HT1080 with ED₅₀ values of 7.5, 7.5, and 4.9 μ g/ml, respectively (Lee et al., 2001).





Moreover, alisol F 24-acetate (93) and alisol B 23-acetate (47) are found inducing cell apoptosis via inhibiting P-glycoprotein mediation and reversing the multidrug resistance in cancer cell lines (Wang et al., 2004; Hyuga et al., 2012; Pan et al., 2016).

Alisol B (46) targets on Ca^{2+} -ATP enzymes in the sarcoplasmic reticulum or endoplasmic reticulum to induce

autophagy of cancer cells (Law et al., 2010). This compound can also induce cell apoptosis by inhibiting the invasion and metastasis of SGC7901 cells (Xu et al., 2009).

Alisol B 23-acetate (47) can inhibit the proliferation of PC-3 prostate cancer (Huang et al., 2006), and induce the apoptosis of lung cancer A549 and NCI-H292 cells through the mitochondrial caspase pathway (Wang et al., 2018). Alisol B 23-acetate (47)





obviously inhibits the proliferation, migration and invasion of ovarian cancer cell lines and induces accumulation of the G1 phase in a concentration-dependent manner. The protein levels of cleaved poly ADP-ribose polymerase (PARP) and the ratio of Bax/Bcl-2 are up-regulated, while the levels of CDK4, CDK6 and cyclin D1 are down-regulated after alisol B 23-acetate (47) treatment. Moreover, it can up-regulate the expression levels of IRE1 α and Bip, and down regulate MMP-2 and MMP-9 in a dose-and time- dependent manner (Zhang et al., 2016). However, current studies of *Alisma* triterpenoids are limited into drug screening *in vitro*, and their anticancer activities need to be validated *in vivo*.

Lipid-Lowering Effects

One of *A. orientale* traditional effects is to treat hyperlipidemia. Studies have shown that the extracts of A. orientale tubers have potential effects on hyperlipidemia diseases (Park et al., 2014; Jang et al., 2015; Li et al., 2016; Miao et al., 2017). Alisol B

23-acetate (47) and alisol A 24-acetate (2) reduce the levels of TC and LDL-C in hyperlipidemia mice via inhibiting the activity of HMG-CoA reductase (Murata et al., 1970; Xu et al., 2016). According to the evaluations of alisols on inhibiting pancreatic lipase, the IC50 of alisol F 24-acetate (93) on pancreatic lipase was 45.5 μ M (Cang et al., 2017). Studies results show that alisol B 23-acetate (47) can bound plasma protein (Xu et al., 2014).

Alisol A (1), alisol A 24-acetate (2) and alisol B (46) can decrease TG level in plasma by improving lipoprotein lipase (LPL) activity (Xu et al., 2018). The effects of alisols with epoxy aliphatic chain at C-17 on LPL are stronger than those with an open aliohatic chain at C-17. Hydroxyl groups submitted at C-14, C-22, C-28, C-30, and an acetyl group at C-29 are necessary for lipid-regulation action of alisols.

Anti-inflammatory

Alisol B 23-acetate (47) prevents the production of NO in RAW264.7 cells by inhibiting iNOS mRNA expression



(Kim et al., 1999). Alisol A 24-acetate (2) effectively alleviates liver steatosis by down-regulating SREBP-1c, ACC, FAS genes and up-regulating CPT1 and ACOX1 genes to activate AMPK signaling pathway and inhibit inflammatory cytokines TNF- α , IL-6 levels (Zeng et al., 2016). In addition, alisol B (46) and alisol B 23-acetate (47) significantly inhibit the production of leukotriene and the release of β -hexosaminidase in the concentrations of 1–10 mM (Lee et al., 2012).

Antibacterial

Alisol B (46), alisol B 23-acetate (47), alisol C 23-acetate (59), and alisol A 24-acetate (2) have significant bacteriostatic actions on four gram positive and four gram negative antibiotic resistant strains with the MICs ranged from 5 to 10 μ g/ml (Jin et al., 2012). In addition, alisol A (1), 25-o-ethylalisol A (16), 11-deoxyalisol A (4), alisol E 24-acetate (15) and 25-anhydroalisol F (97) fight off gram-positive strains of bacillus subtilis and staphylococcus aureus with MICs ranged from 12.5 to 100 mg/ml (Ma et al., 2016).

Antiviral

Studies have shown that alisols from A. orientale exhibit obvious anti-hepatitis b virus effect (Jiang et al., 2006). Alisol F (92) and alisol F 24-acetate (93) significantly inhibit the secretion of HBV surface antigen with an IC_{50} value of 7.7 and 0.6 μ M, and

HBVe antigen secretion with an IC₅₀ value of 5.1 and 8.5 μ M, respectively. A series of derivatives of alisol A (1) obtained after structural modification also showed potential effect (Zhang et al., 2008, 2009).

STRUCTURE MODIFICATION

Alisol B 23-acetate can induce apoptosis and autophagy in cancer cell lines (Xu et al., 2015), and structure modification on alisol B 23-acetate (47) allows to obtain a diverse of derivatives (Lee et al., 2002). Alisol B 23-acetate (47) reacts with m-chloroperoxybenzoic acid (mCPBA) in CH₂Cl₂ at room temperature to gain 13β, 17β-epoxy-23-acetate-alisol B (67), and reacts with NH2OH.HCl in pyridine and MeOH to achieve amination at C-3. Deacetylation of alisol B 23-acetate (47) by NaOH yields alisol B (46). Although there is no significant difference of inhibition effect on B16-F10 and HT1080 cell lines between 13β, 17β-epoxy-23-acetate-alisol B (67) (ED50 values of 17 and 18µg/ml) and alisol B 23-acetate (47) (ED50 values of 20 µg/ml, respectively), alisol B (46) (B16-F10 and HT1080 with ED50 values of 5.2 and 3.1 ug/ml), amination at C-3 of alisol B 23-acetate (47) (with ED50 values of 7.5 and 5.1 ug/ml) show exhibited greater activation against B16-F10 and HT1080 cancer cells. It indicates that deacetylation of C-23 and amination at



C-3 significantly enhance the inhibition effect on B16-F10 and HT1080 cell lines.

Four hydroxyl groups of alisol A (1) are usually the target sites for modification by reacting with acetic anhydride in N, N'- dicyclohexylcarbodiimide and 4-dimethylamnopyridine. Alisol A (1) can also dehydrate by SOCl₂ in the presence of anhydrous pyridine. The assessments of anti-hepatitis B virus (HBV) activities suggest alisol A (1) analogs with acetoxyl groups at C-11, C-23, C-24 or the epoxy ring at C-13 and C-17 increase the effects on HBV. Dehydration at C-25/C-26 enhances its sensitivity on HBV (Zhang et al., 2008, 2009).

Biotransformation of alisol A (1) also derives a series of active compound by several bacteria strains, such as *C. elegans* AS 3.2028 and *P. janthinellum* AS 3.510. Alisol A (1) can inhibit the proliferation of HCE-2 cells on the IC₅₀ of 99.65 \pm 2.81 μ M (Zhang et al., 2017). The activity screening results reveal hydroxylation at C-7 and C-12 increases the inhibiting effects of alisol A (1) on human carboxylesterase 2 (IC₅₀ values of 7.39 \pm 1.21 and 3.73 \pm 0.76 μ M) and the acetyl group at C-23 or C-24 also increases its inhibition effect on HCE-2 cells (IC₅₀ values of 3.78 \pm 0.21 and 6.11 \pm 0.46 μ M).

Taken together, epoxidation at C-13 and C-17, hydroxylation at C-23, C-7/C-12, amination at C-3, and dehydration at C-25/C-26 contribute to the activities of protostane tetracyclic skeleton of *A. orientale*, including anticancer activity, antihepatitis B virtus, and the inhibiting activity on human carboxylesterase 2.

REFERENCES

- Cang, J., Wang, C., Huo, X. K., Tian, X. G., Sun, C. P., Deng, S., et al. (2017). Sesquiterpenes and triterpenoids from the rhzomes of *Alisma orientalis* and their pancreatic lipase inhibitory activities. *Phytochem. Lett.* 19, 83–88. doi: 10.1016/j.phytol.2016.12.017
- Chen, H., Yang, T., Wang, M. C., Chen, D. Q., Yang, Y., and Zhao, Y. Y. (2018). Novel RAS inhibitor 25-O-methylalisol F attenuates epithelialto-mesenchymal transition and tubulo-interstitial fibrosisi by selectively inhibiting TGF-β-mediated Smad3 phosphorylation. *Phytomedicine* 42, 207–218. doi: 10.1016/j.phymed.2018.03.034
- Chinese Pharmacopoeia Commission (2015). Pharmacopoeia of the People's Republic of China. Beijing: China Medical Science.
- Choi, E., Jang, E., and Lee, J. H. (2019). Pharmacological activities of *Alisma orientale* against nonalcoholic fatty liver disease and metabolic syndrome: literature review. *Evid. Based Comple. Alternat. Med.* 2019:2943162. doi: 10.1155/2019/2943162
- Flora of China Committee (1992). Flora of China. Beijing: Science Press Beijing. 127-145.
- Fukuyama, Y., Pei-Wu, G., Rei, W., Yamada, T., and Nakagawa, K. (1988). 11deoxyalisol C and alisol D: new protostane-type triterpenoids from *Alisma plantago-aquatica*. *Planta Med*. 1988,445–447. doi: 10.1055/s-2006-962495
- Han, C. W., Kwun, M. J., Kim, K. H., Choi, J. Y., Oh, S. R., Ahn, K. S., et al. (2013). Ethanol extract of alismatis rhizoma reduces acute lung inflammation by suppressing NF-kB and activating Nrf2. *J. Ethnopharmacol.* 146, 402–410. doi: 10.1016/j.jep.2013.01.010
- Hu, X. Y., Guo, Y. Q., Gao, W. Y., Chen, H. X., and Zhang, T. J. (2008b). A new triterpenoid from *Alisma orientalis. Chin. Chem. Lett.* 19, 438–440. doi: 10.1016/j.cclet.2008.01.019
- Hu, X. Y., Guo, Y. Q., Gao, W. Y., Zhang, T. J., and Chen, H. X. (2008a). Two new triterpenes from the rhizomes of *Alisma orientalis*. J. Asian Nat. Prod. Res. 10, 487–790. doi: 10.1080/10286020801948441

CONCLUSION

The present work systematically summarized the information concerning the phytochemistry, bioactivities and structure modification of triterpenoids in *Alisma* species. To date, more than 100 protostane-type terterpenoids have been isolated and identified. Alisols are reported with anticancer, lipid-regulating, anti-inflammatory, antibacterial, and antiviral activities. Structure modification might contribute to the investigation of the therapeutic potential of alisols.

AUTHOR CONTRIBUTIONS

MJ designed the review and was responsible for the study conception. PW and MJ wrote the paper. PW, TS, and RS contributed to summarizing the phytochemistry and structure modification studies on triterpenoids. MH, RW, and JL contributed to summarizing the bioactivity studies on triterpenoids.

FUNDING

This work was supported by the National major new drug creation science and technology major special support project (Nos. 2018ZX09735-002 and 2018YFC1707904) and the Natural Science Foundation of Tianjin (No. 18JCZDJC97700).

- Huang, Y. T., Huang, D. M., Chueh, S. C., Teng, C. M., and Guh, J. H. (2006). Alisol B acetate, a triterpene from alismatis rhizoma, induces bax nuclear translocation and apoptosis in human hormone-resistant prostate cancer PC-3 cells. *Cancer Lett.* 231, 270–278. doi: 10.1016/j.canlet.2005.02.011
- Hyuga, S., Shiraishi, M., Hori., A., Hyuga, M., and Hanawa, T. (2012). Effect of kampo medicines on MDR-1-mediated multidrug resistance in human hepatocellular carcinoma HuH-7/PTX cells. *Biol. Pharm. Bull.* 35, 1729–1739. doi: 10.1248/bpb.b12-00371
- Jang, M. K., Han, Y. R., Nam, J. S., Han, C. W., Kim, B. J., Jeong, H. S., et al. (2015). Protective effect of *Alisma orientale* extract against hepatic steatosis via inhibition of endoplasmic reticulum stress. *Int. J. Mol. Sci.* 16, 26151–26165. doi: 10.3390/ijms161125944
- Jiang, Z. Y., Zhang, X. M., Zhang, F. X., Liu, N., Zhao, F., Zhou, J., et al. (2006). A new triterpene and anti- hepatitis B virus active compounds from *Alisma* orientalis. Plant Med. 72, 951–954. doi: 10.1055/s-2006-947178
- Jin, H. G., Jin, Q. L., Kim, A. R., Choi, H., Lee, J. H., Kim, Y. S., et al. (2012). A new triterpenoid from *Alisma oientale* and their antibacterial effect. *Arch. Pharm. Res.* 35, 1919–1926. doi: 10.1007/s12272-012-1108-5
- Jin, Q. H., Zhang, J. Q., Hou, J. J., Lei, M., Liu, C., Wang, X., et al. (2019). Novel C-17 spirost protostane-type triterpenoids from *Alisma plantago-aquatica* with anti-inflammatory activity in Caco-2 cells. *Acta Pharm. Sin. B* 9, 809–818. doi: 10.1016/j.apsb.2019.04.002
- Kim, K. H., Song, H. H., Ahn, K. S., Oh, S. R., Sadikot, R. T., and Joo, M. (2016). Ethanol extract of the tuber of *Alisma orientale* reduces the pathologic features in a chronic obstructive pulmonary disease mouse model. *J. Ethnopharmacol.* 188, 21–30. doi: 10.1016/j.jep.2016.05.004
- Kim, N. Y., Kang, T. H., Pae, H. O., Choi, B. M., Chung, H. T., Myung, S. W., et al. (1999). *In vitro* inducible nitric oxide synthesis inhibitors from *Alismatis rhizoma. Biol. Pharm. Bull.* 22, 1147–1149. doi: 10.1248/bpb.2 2.1147
- Law, B. Y. K., Wang, M. F., Ma, D. L., Al-Mousa, F., Michelangeli, F., Cheng, S. H., et al. (2010). Alisol B, a novel inhibitor of the

sarcoplasmic/endoplasmic reticulum Ca(2+) ATPase pump, induces autophagy, endoplasmic reticulum stress, and apoptosis. *Mol. Cancer Ther.* 9, 718–730. doi: 10.1158/1535-7163.MCT-09-0700

- Lee, J. H., Kwon, O. S., Jin, H. G., Woo, E. R., Kim, Y. S., and Kim, H. P. (2012). The rhizomes of *Alisma orientale* and Alisol derivatives inhibit allergic response and experimental atopic dermatitis. *Biol. Pharm. Bull.* 35, 1581–1587. doi: 10.1248/bpb.b110689
- Lee, S. M., Kho, Y. H., Min, B. S., Kim, J. H., Na, M. K., Kang, S. J., et al. (2001). Cytotoxic triterpenoides from *Alismatis rhizome. Arch. Pharm. Res.* 24, 524–526. doi: 10.1007/BF02975158
- Lee, S. M., Min, B., and Bae, K. (2002). Chemical modification of alisol B 23-acetate and their cytotoxic activity. Arch. Pharm. Res. 25, 608–612. doi: 10.1007/BF02976929
- Li, H. M., Chen, X. J., Luo, D., Fan, M., Zhang, Z. J., Peng, L. Y., et al. (2017). Protostane-type triterpenoids from *Alisma orientale. Chem. Biodivers*. 14:e1700452. doi: 10.1002/cbdv.201700452
- Li, S., Jin, S. N., Song, C. W., Chen, C., Zhang, Y., Xiang, Y., et al. (2016). The metabolic change of serum lysophosphatidylcholines involved in the lipid lowering effect of triterpenes from *Alismatis rhizoma* on high-fat diet induced hyperlipidemia mice. *J. Ethnopharmacol.* 177, 10–18. doi: 10.1016/j.jep.2015.11.017
- Ma, Q. J., Han, L., Bi, X. X., Wang, X. B., Mu, Y., Guan, P. P., et al. (2016). Structures and biological activities of the triterpenoids and sesquiteropenoids from *Alisma orientale. Phytochemistry* 131, 150–157. doi: 10.1016/j.phytochem.2016. 08.015
- Mai, Z. P., Zhou, K., Ge, G. B., Wang, C., Huo, X. K., Dong, P. P., et al. (2015). Protostane triterpenoids from the rhizome of *Alisma orientale* exhibit inhibitortory effects on human carboxylesterase2. *J. Nat. Prod.* 78, 2372–2380. doi: 10.1021/acs.jnatprod.5b00321
- Matsuda, H., Kageura, T., Toguchida, I., Murakami, T., Kishi, A., and Yoshikawa, M. (1999). Effects of sesquiterpenes and triterpenes from the rhizome of *Alisma orientale* on nitric oxide production in lipopolysaccharideactivated macrophages: absolute stereostructures of alismaketones B 23-acetate and -C 23-acetate. *Bioorg. Med. Chem. Lett.* 9, 3081–3086. doi: 10.1016/S0960-894X(99)00536-3
- Miao, H., Zhang, L., Chen, D. Q., Chen, H., Zhao, Y. Y., and Ma, S. C. (2017). Urinary biomarker and treatment mechanism of rhizoma alismatis on hyperlipidemia. *Biomed. Chromatograp.* 31:e3829. doi: 10.1002/bmc.3829
- Murata, T., Shinohara, M., Hirata, T., Kamiya, K., Nishikawa, M., and Miyamoto, M. (1968). New triterpenes of alisma plantago-aquatica L. Var. Orientale samuels. *Tetrahedron Lett.* 9, 103–108. doi: 10.1016/S0040-4039(01)98735-0
- Murata, T. Y., Imai, T., Hirata, T., and Miyamoto, M. (1970). Biological-active trieterpenes of Alismatis rhizoma.I. isolation of the Alisols rhizoma. Chem. Pharm. Bull. 18, 1347–1353. doi: 10.1248/cpb.18.1347
- Nakajma, Y., Satoh, Y., Katsumata, M., Tsujiyama, K., Ida, Y., and Shoji, J. (1994). Terpenoids of Alisma Orientale rhizome and the crude drug Alismatis Rhizoma. Phytochemistry 36, 119–127. doi: 10.1016/S0031-9422(00)97024-9
- Pan, G. X., Li, T. T., Zeng, Q. Q., Wang, X. M., and Zhu, Y. (2016). Alisol F 24 acetate enhances chemosensitivity and apoptosis of MCF-7/DOX cell by inhibiting P-glycoprotein-mediated drug efflux. *Molecules* 21:183. doi: 10.3390/molecules21020183
- Park, Y. J., Kim, M. S., Kim, H. R., Kim, J. M., Hwang, J. K., Yang, S. H., et al. (2014). Ethanol extract of Alimatis rhizome inhibits adipocyte differentiation of OP9 cells. Evid. Based Comple. Altern. Med. 2014:415097. doi: 10.1155/2014/415097
- Peng, B., Nielsen, L. K., Kampranis, S. C., and Vickers, C. E. (2018). Engineered protein degradation of farnesyl pyrophosphate synthase is an effective regulatory mechanism to increase monoterpene production in *Saccharomyces cerevisiae*. *Metab. Eng.* 47, 83–93. doi: 10.1016/j.ymben.2018.02.005
- Peng, G. P., and Lou, F. C. (2001). Study on triterpenes in rhizoma alismatis from Sichuan. Nat. Prod. Res. Dev. 13, 1–4. doi: 10.1633/j.1001-6880.2001.04.001
- Peng, G. P., Zhu, G. Y., and Lou, F. C. (2002a). Study on two new constituents of triterpenes from rhizoma alismatis II. *Nat. Prod. Res. Dev.* 14, 5–8. doi: 10.1633/j.10001-6880.2002.04.002
- Peng, G. P., Zhu, G. Y., and Lou, F. C. (2002b). Study on triterpenes in rhizoma alismatis from Sichuan III. Nat. Prod. Res. Dev. 14, 7–10. doi: 10.16333/j.1001-6880.2002.06.003
- Shen, X. Y., Gu, W., Zhou, J. J., Wu, Q. N., Xu, F., and Gao, J. (2013). Gene cloning of squalene synthase in *Alisma orientalis* and its bioinformatic analysis.

Chin. Trad. Herb. Drug. 44, 604–609. doi: 10.7501/j.issn.0253-2670.2013. 05.021

- Shu, Z. H., Pu, J., Chen, L., Zhang, Y. B., Rahman, K., Qin, L., et al. (2016). *Alisma orientale*: ethnopharmacology, phytochemistry and pharmacology of an important traditional chinese medicine. *Am. J. Chin. Med.* 2, 227–251. doi: 10.1142/S0192415X16500142
- Tian, T., Chen, H., and Zhao, Y. Y. (2014). Traditional uses, phytochemistry, pharmacology, toxicology and quality control of *Alisma orientale* (Sam.) juzep: a review. *J. Ethnopharmacol.* 158, 373–387. doi: 10.1016/j.jep.2014. 10.061
- Vinokur, J. M., Korman, T. P., Cao, Z., and Bowie, J. U. (2014). Evidence of a novel mevalonate pathway in archaea. *Biochemistry* 25, 4161–4168. doi: 10.1021/bi500566q
- Wang, C., Huo, X. K., Luan, Z. L., Cao, F., Tian, X. G., Zhao, X. Y., et al. (2017a). Alismanin A, a triterpenoid with a C34 skeleton from *Alisma orientale* as a natural agonist of human pregnane X receptor. *Org. Lett.* 19, 5645–5648. doi: 10.1021/acs.orglett.7b02738
- Wang, C., Zhang, J. X., Shen, X. L., Wan, C. K., Tse, K. W., and Fong, W. F. (2004). Reversal of P-glycoprotein-mediated multidrug resistance by alisol B 23-acetate. *Biochem. Pharmacol.* 68, 843–855. doi: 10.1016/j.bcp.2004.05.021
- Wang, J. X., Li, H. Z., Wang, X. N., Shen, T., Wang, S. Q., and Ren, D. M. (2018). Alisol B-23-acetate, a tetracyclic triterpenoid isolated from *Alisma orientale*, induces apoptosis in human lung cancer cells via the mitochondrial pathway. *Biochem. Biophys. Res. Commun.* 2018, 1015–1021. doi: 10.1016/j.bbrc.2018.10.022
- Wang, Y. L., Zhao, J. C., Liang, J. H., Tian, X. G., Huo, X. K., Feng, L., et al. (2017b). A bioactive new protostane-type triterpenoid from *Alisma plantago-aquatica* subsp. *orientale* (sam.) juzep. Nat. Prod. Res. 11, 776–781. doi: 10.1080/14786419.2017.1408106
- Xin, X. L., Mai, Z. P., Wang, X. C., Liang, D. S., and Zhang, B. (2016). Protostane alisol derivatives from the rhizome of *Alisma orientale*. *Phytochem. Lett.* 16, 8–11. doi: 10.1016/j.phytol.2016.02.008
- Xin, X. L., Zhao, X. Y., Huo, X. K., Tian, X. G., Sun, C. P., Zhang, H. L., et al. (2018).
 Two new protostane-type triterpnoids from *Alisma orientalis*. *Nat. Prod. Res.* 32, 189–194. doi: 10.1080/14786419.2017.1344660
- Xu, D., Zhang, H. D., and Xie, X. (2012). New triterpenoids from rhizoma alisma. *Chin. Trad. Herb. Drugs* 43, 841–843.
- Xu, F., Lu, Q. A., Gu, W., Chen, J., Fang, F., Zhao, B., et al. (2018). Studies on the lipid-regulating mechanism of alisol-based compounds on lipoprotein lipase. *Bioorg. Chem.* 80, 347–360. doi: 10.1016/j.bioorg.2018.07.001
- Xu, F., Wu, Q. N., Chen, J., Gu, W., Fang, F., Zhang, L. Q., et al. (2014). The binding mechanisms of plasma protein to active compounds in *Alisma orientale* rhizomes (*Alismatis Rhizoma*). *Bioorg. Med. Chem. Lett.* 24, 4099–4105. doi: 10.1016/j.bmcl.2014.07.065
- Xu, F., Yu, H., Lu, C., Chen, J., and Gu, W. (2016). The cholesterol lowering effect of alisol acetate based on HMG-CoA reductase and its molecular mechanism. *Evid. Based Complement. Altern. Med.* 2016:4753852. doi: 10.1155/2016/4753852
- Xu, W., Li, T., Qiu, J. F., Wu, S. S., Huang, M. Q., Lin, L. G., et al. (2015). Antiproliferative activities of terpenoid isolated from *Alisma orirntalis* and their structure activity relationships. *Anticancer Agents Med. Chem.* 15, 228–235. doi: 10.2174/1871520614666140601213514
- Xu, Y. H., Zhao, L. J., and Li, Y. (2009). Alisol B acetate induces apoptosis of SGC7901 cells via mitochondrial and phosphatidylinositol 3kinases/Akt signaling pathways. World J. Gastroenterol. 15, 2870–2877. doi: 10.3748/wjg.15.2870
- Yi, J., Bai, R., An, Y., Liu, T. T., Liang, J. H., Tian, X. G., et al. (2019). A natural inhibitor from *Alisma orientale* against human carboxylesterase 2: kinetics, circular dichroism spectroscopic analysis, and docking simulation. *Int. J. Biol. Macromol.* 133, 184–189. doi: 10.1016/j.ijbiomac.2019. 04.099
- Yoshikawa, M., Hatakeyama, S., Tanaka, N., Fuhuda, Y., Yamahara, J., and Murakami, N. (1993). Crude drug from aquatic plants. I. on the constituents of *Alismatis Rhizoma*. (1). absolute stereostructures of Alisols E 23-acetate, F, and G, three new protostane-type triterpenes from Chinese *Alismatis Rhizoma*. *Chem. pharm. Bull.* 41, 1948–1954. doi: 10.1248/cpb.41.1948
- Yoshikawa, M., Muraakami, T., Ikebata, A., Ishikado, A., Murakami, N., Yamahara, J., et al. (1997). Absolute stereostructures of Alismalactone

23-acetate and Alismaketone-A-23-acetate, new seco-protostane and protostane-type triterpenes with vasorelaxant effects from Chinese *Alismatis Rhizoma. Chem. Pharm. Bull.* 45, 756–758. doi: 10.1248/cpb. 45.756

- Yoshikawa, M., Tomohro, N., Murakami, T., Ikebata, A., Matsude, H., Matsude, H., et al. (1999). Studies on *Alismatis Rhizoma*. III. stereostructures of new protostane-type triterpenes, aliaols H, I, J-23-acetate, K-23-acetate, L-23-acetata, M-23-acetate, and N-23-acetate, from the dried rhizome of *Alisma orientale*. *Chem. Pharm. Bull.* 147, 524–528. doi: 10.1248/cpb. 47.524
- Yoshikawa, M., Yamaguchi, S., Chatani, N., Matsuoka, T., Yamahara, J., Murakami, N., et al. (1994). Crude drugs from aquaticplants. III. quantitative analysis of triterpene constituents in *Alismatis rhizoma* by means of high performance liquid chromatography on the chemical change of the constituents during *Alismatis rhizoma* processing. *Yakuqaku Zasshi*. 114, 241–247. doi: 10.1248/yakushi1947. 114.4_241
- Zeng, L., Tang, W. J., Yin, J. J., Feng, L. J., Li, Y. B., Yao, X. R., et al. (2016). Alisol A 24-acetate prevents hepatic steatosis and metabolic disorders in HepG2 cells. *Cell. Physiol. Biochem.* 40, 453–464. doi: 10.1159/000452560
- Zhang, L. L., Xu, Y. L., Tang, Z. H., Xu, X. H., Chen, X., Li, T., et al. (2016). Effects of alisol B 23-acetate on ovarian cancer cells: G1 phase cell cycle arrest, apoptosis, migration and invasion inhibition. *Phytomedicine* 23, 800–809. doi: 10.1016/j.phymed.2016.04.003
- Zhang, Q., Jiang, Z. Y., Luo, J., Cheng, P., Ma, Y. B., Zhang, X. M., et al. (2008). Anti-HBV agents. part 1: synthesis of alisol A derivatives: a new class of hepatitis B virus inhibitors. *Bioorg. Med. Chem. Lett.* 18, 4647–4650. doi: 10.1016/j.bmcl.2008.07.012
- Zhang, Q., Jiang, Z. Y., Luo, J., Liu, J. F., Ma, Y. B., Guo, R. H., et al. (2009). Anti-HBV agents. part 2: synthesis and *in vitro* anti-hepatitis B virus activities of alisol A derivatives. *Bioorg. Med. Chem. Lett.* 19, 2148–2153. doi: 10.1016/j.bmcl.2009.02.122
- Zhang, T. J., Bai, G., Chen, C. Q., Xu, J., Han, Y. Q., and Long, S. X. (2018). Research pathways of Q-marker of compound Chinese medicine based on five principles. *Chin. Trad. Herb. Drugs* 49, 1–13. doi: 10.7501/j.issn.0253-2670.2018. 01.001

- Zhang, Z. J., Huo, X. K., Tian, X. G., Feng, L., Ning, J., Zhao, X. Y., et al. (2017). Novel protostane-type triterpenoids with inhibitory human carboxylesterase 2 activities. *Rsc. Adv.* 7, 28702–28710. doi: 10.1039/C7RA04841F
- Zhao, M., Godecke, T., Gunn, J., Duan, J. A., and Che, C. T. (2013). Protostane ang fusidane triterpenes: a mini- review. *Molecules* 18, 4054–4080. doi: 10.3390/molecules18044054
- Zhao, M., Xu, L. J., and Che, C. T. (2007). Alisolide, alisols O and P from the Alisma orientale. Phytochemistry 69, 527–532. doi: 10.1016/j.phytochem.2007.06.014
- Zhao, W. L., Huang, X. Q., Li, X. Y., Zhang, F. F., Chen, S. N., Ye, M., et al. (2015). Qualitative and quantitative analysis of major teiterpenoids in *Alismatis rhizome* by high performance liquid chromatography/diode-array detector/quadrupole-time-of-flight mass spectrometry and ultra-performance liquid chromatography/triple quadrupole mass spectrometry. *Molecules* 20, 13958–13981. doi: 10.3390/molecules200813958
- Zheng, Y. F., Zhu, Y. L., and Peng, G. P. (2006). Transformation of alisol B 23acetate in processing drug of *Alisma orientale*. *Chin. Trad. Herb. Drugs* 37, 1479–1482.
- Zhou, C., Tian, R., Gu, W., Geng, C., Wu, Q. N., and Xu, F. (2018). Prokaryotic expression, functional verification and immunoassay of farnesyl pyrophosphate synthase of *Alisma orientale* (sam.) juzep. *Acta Pharm. Sin.* 53, 1571–1577. doi: 10.16438/j.0513-4870.2018-0401
- Zhu, Y. L., and Peng, G. P. (2006). Progress in the study on chemical constituents of *Alisma orientalis*. *Nat. Prod. Res. Dev.* 18, 348–351. doi:10.16333/j.1001-6880.2006.02.041

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Wang, Song, Shi, He, Wang, Lv and Jiang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.